Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

RIVASTIGMINE

RIVASTIGMINE TARTRATE

Standard Dose
2MG/ML
Max Dose
Refer to approved labeling
Primary Use
Marketing status: None (Tentative Approval)
Summary

Approval overview RIVASTIGMINE is listed in Drugs@FDA under application 077363 (ANDA).

Marketing status: None (Tentative Approval) Active ingredient RIVASTIGMINE TARTRATE Form and strength SOLUTION; ORAL - 2MG/ML Sponsor RANBAXY Submission history Latest submission status date: 2005-12-21 00:00:00.

Structured Monograph

Clinical summary

Approval overview RIVASTIGMINE is listed in Drugs@FDA under application 077363 (ANDA). Marketing status: None (Tentative Approval) Active ingredient RIVASTIGMINE TARTRATE Form and strength SOLUTION; ORAL - 2MG/ML Sponsor RANBAXY Submission history Latest submission status date: 2005-12-21 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: None (Tentative Approval)

Interaction Notes

  • No interaction notes stored yet.